Systemic lupus erythematosus (SLE), commonly known as lupus, is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues. It can affect the skin, joints, kidneys, blood cells, lungs, heart, and other organs. Although conventional medicines help many patients control lupus, some continue to experience disease flares or persistent symptoms despite treatment.
Advances in lupus treatment have introduced targeted medicines called biologic therapies. Two important options are belimumab and anifrolumab. Both work by targeting specific parts of the immune system, but they act through different pathways and are not suitable for every patient.
If you are searching for the difference between belimumab and anifrolumab for lupus, understanding their mechanisms, uses, benefits, and risks can help you have a more informed discussion with your rheumatologist.
What Is Belimumab for Lupus?
Belimumab is a biologic medicine used alongside standard treatment for selected patients with active systemic lupus erythematosus. It is also used in certain patients with active lupus nephritis, a condition in which lupus causes inflammation and damage to the kidneys.
Belimumab targets a protein called B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS).
B cells are immune cells that can produce antibodies. In lupus, abnormal B-cell activity contributes to the production of autoantibodies that may attack healthy tissues.
By blocking BAFF, belimumab reduces a signal that helps certain B cells survive and function. This can help control abnormal immune activity and reduce lupus disease activity in appropriate patients.
Who May Benefit From Belimumab?
A rheumatologist may consider belimumab for patients who:
- Have active lupus despite receiving standard treatment.
- Experience repeated lupus flares.
- Have persistent disease activity that requires treatment adjustment.
- Need a steroid-sparing treatment strategy.
- Have certain forms of active lupus nephritis and need additional treatment alongside standard therapy.
Belimumab is not a cure for lupus. Its purpose is to improve disease control and help reduce the risk of flares in suitable patients.
What Is Anifrolumab for Lupus?
Anifrolumab is another biologic medicine used for selected adults with moderate-to-severe systemic lupus erythematosus who are receiving standard treatment.
It targets the type I interferon receptor.
Type I interferons are immune-system proteins involved in antiviral defence and immune signalling. In many people with lupus, this pathway is overactive and contributes to inflammation and disease activity.
Anifrolumab blocks signalling through the type I interferon receptor, helping reduce the effects of this pathway.
Who May Benefit From Anifrolumab?
A rheumatologist may consider anifrolumab for adults with active lupus when standard treatment does not provide adequate disease control.
It may be considered for patients with certain skin or joint manifestations, persistent disease activity, or difficulty reducing corticosteroid treatment.
However, anifrolumab is not recommended for severe active lupus nephritis or severe active central nervous system lupus, because its effectiveness has not been established in these situations. Treatment choices for these serious manifestations require a different, carefully individualized approach.
Belimumab vs Anifrolumab: Key Differences
Although both medicines are biologic therapies, they target different immune pathways.
| Feature | Belimumab | Anifrolumab |
| Type of treatment | Biologic therapy | Biologic therapy |
| Main target | BAFF/BLyS protein | Type I interferon receptor |
| Main action | Reduces survival signals for certain B cells | Blocks type I interferon signalling |
| Use in systemic lupus | Used for selected patients with active SLE | Used for selected adults with moderate-to-severe SLE |
| Use in lupus nephritis | An approved treatment option for selected patients, alongside standard therapy | Not recommended for severe active lupus nephritis |
| Administration | Intravenous infusion or subcutaneous injection, depending on formulation and indication | Intravenous infusion; subcutaneous formulations may be available depending on local approval |
| Important safety considerations | Infections, infusion or injection reactions, and mood-related warnings | Infections, infusion reactions, and an increased risk of shingles |
| Treatment goal | Improve disease control and help reduce flares | Improve disease control and help reduce disease activity |
Availability, approved indications, and administration options can differ by country. Your rheumatologist will consider local approvals and your individual clinical situation.
Which Is More Effective: Belimumab or Anifrolumab?
There is no single answer for every patient.
Both medicines have demonstrated benefits in clinical trials when added to standard lupus treatment. However, there is no definitive head-to-head clinical trial establishing that one is universally better than the other.
A 2026 systematic review and network meta-analysis compared evidence from separate clinical trials. It found that both medicines improved the likelihood of achieving a lupus disease response compared with placebo. Some outcomes favoured anifrolumab, but the findings were based largely on indirect comparisons and should not be interpreted as proof that it is the best treatment for every patient.
The choice depends on several factors.
1. Type of Lupus Manifestations
The organs affected by lupus play an important role in treatment selection.
For example, belimumab has an established role in selected patients with active lupus nephritis, in combination with standard therapy. Anifrolumab may be considered for certain adults with active non-renal lupus.
2. Response to Previous Treatment
If lupus remains active despite appropriate treatment, a rheumatologist may consider a biologic medicine.
The doctor will review which symptoms remain active, how frequently flares occur, and whether previous medicines were effective or caused side effects.
3. Steroid Reduction Goals
Long-term corticosteroid use can increase the risk of osteoporosis, high blood pressure, diabetes, weight gain, and infections.
Both biologic medicines may help some patients achieve better disease control and reduce their need for corticosteroids. However, steroid reduction must be gradual and guided by the treating doctor.
4. Individual Safety Considerations
A patient’s history of infections, other medical conditions, previous treatment reactions, and vaccination status may influence the choice.
For example, the increased risk of herpes zoster, commonly called shingles, is an important consideration with anifrolumab.
Belimumab vs Anifrolumab for Lupus Nephritis
Lupus nephritis develops when lupus-related immune activity causes inflammation in the kidneys. It may lead to protein in the urine, blood in the urine, high blood pressure, or declining kidney function.
Some patients have few obvious symptoms in the early stages, making regular urine and blood testing essential.
Belimumab is an established treatment option for selected patients with active lupus nephritis. It is used alongside standard treatment rather than as a replacement for the complete kidney treatment plan.
Anifrolumab, on the other hand, is not recommended for severe active lupus nephritis because its effectiveness has not been established for this condition.
Treatment for lupus nephritis depends on the kidney biopsy findings, kidney function, degree of inflammation, previous treatment response, and other individual factors.
Important: Not every patient with lupus nephritis needs belimumab. A nephrologist and rheumatologist may work together to determine the most appropriate treatment plan.
What Are the Side Effects of Belimumab?
Belimumab can cause side effects, although not everyone experiences them.
Possible side effects include:
- Nausea or diarrhoea.
- Fever.
- Infusion-related reactions.
- Injection-site reactions.
- Respiratory or other infections.
- Headache.
Mood changes and depression are also important safety considerations. Patients should inform their healthcare provider about a history of depression or other mental health concerns and report new or worsening mood symptoms.
Before treatment, the doctor will review the patient’s medical history, current medicines, infection risks, and other relevant factors.
Seek medical advice if you develop persistent fever, signs of infection, a significant allergic reaction, or concerning changes in mood.
What Are the Side Effects of Anifrolumab?
Anifrolumab can also cause side effects. Commonly reported problems include:
- Upper respiratory tract infections.
- Bronchitis.
- Infusion-related reactions.
- Cough.
- Shingles, also known as herpes zoster.
Because anifrolumab affects immune signalling, doctors assess infection risks before and during treatment.
Tell your doctor if you have an active infection or a history of recurrent infections. Vaccination history should also be reviewed before treatment, and live vaccines are generally avoided during therapy.
Seek prompt medical advice if you develop a painful blistering rash, fever, or other symptoms that could indicate an infection.
How Are Belimumab and Anifrolumab Given?
The method of administration differs between these medicines.
Belimumab: Depending on the formulation and indication, it can be given as an intravenous infusion or a subcutaneous injection. The schedule depends on the treatment plan.
Anifrolumab: It is administered by intravenous infusion under medical supervision in settings where that formulation is approved.
Treatment schedules and availability can vary by country. Your healthcare provider will explain the appropriate schedule, monitoring requirements, and what to expect during treatment.
Neither medicine should be started, stopped, or changed without medical guidance.
What Tests Are Needed Before Starting Biologic Therapy?
Before recommending belimumab or anifrolumab, a rheumatologist will assess lupus activity and the patient’s overall health.
Depending on the individual situation, this may include:
- Complete blood count.
- Kidney and liver function tests.
- Urine testing for protein or blood.
- Complement levels and relevant lupus autoantibodies.
- Assessment of current disease activity.
- Review of previous infections and infection risks.
- Vaccination history.
- Review of current medicines and previous treatment responses.
Not every patient needs every test. The investigations are selected according to the patient’s symptoms, medical history, and proposed treatment.
Regular follow-up is also important to evaluate how well the medicine is working and whether side effects are developing.
Can Belimumab or Anifrolumab Cure Lupus?
No. Neither medicine cures lupus.
Lupus is a chronic autoimmune condition, and treatment aims to control inflammation, reduce flares, protect organs, and maintain quality of life.
Some patients achieve remission or low disease activity with appropriate treatment. Others need ongoing adjustments to their medicines.
Even when symptoms improve, regular medical follow-up remains important because lupus activity can change over time.
Frequently Asked Questions
1. Is belimumab better than anifrolumab for lupus?
Neither medicine is universally better. Both can benefit selected patients, but they target different immune pathways. The best choice depends on disease manifestations, previous treatment response, safety considerations, and whether the kidneys or other organs are involved.
2. Can anifrolumab treat lupus nephritis?
Anifrolumab is not recommended for severe active lupus nephritis because its effectiveness has not been established for this condition. Belimumab is an established option for selected patients with active lupus nephritis alongside standard therapy.
3. Can these biologics reduce steroid use?
They may help some patients reduce corticosteroid exposure by improving disease control. However, steroid doses must be reduced gradually under medical supervision.
4. Which medicine has fewer side effects?
Both medicines have potential risks, and the safety profile differs. Anifrolumab is associated with an increased risk of shingles, while belimumab has important infection and mood-related safety considerations. Your doctor will assess which risks matter most in your situation.
5. How long does it take for biologic therapy to work?
The response varies between patients. Improvement may develop over weeks or months, and your rheumatologist will assess symptoms, disease activity, and relevant test results over time.
6. Can I take belimumab or anifrolumab with other lupus medicines?
These biologics are generally used alongside standard lupus treatment. However, the combination must be selected carefully. Tell your doctor about all medicines and supplements you take, and do not change your treatment independently.
7. Are these medicines suitable during pregnancy?
Pregnancy planning requires an individualized review of lupus activity and medication safety. If you are pregnant, breastfeeding, or planning pregnancy, discuss your treatment with your rheumatologist before starting or changing a medicine.
Final Thoughts
Belimumab and anifrolumab are important targeted treatments for selected people with systemic lupus erythematosus, but they work differently.
Belimumab targets the BAFF/BLyS pathway and has an established role in selected patients with active lupus nephritis. Anifrolumab blocks type I interferon signalling and may be considered for certain adults with moderate-to-severe non-renal lupus.
There is no single biologic medicine that is best for every patient. The right choice depends on the organs affected, lupus activity, previous treatment response, safety considerations, and individual treatment goals.
If your lupus remains active despite your current medicines or you are finding it difficult to reduce corticosteroids, speak with a rheumatologist about whether biologic therapy may be appropriate.
Individualized treatment and regular monitoring are essential for achieving better lupus control and protecting long-term health.
